UMB-136

• UNSPSC Description:

  UMB-136 is a bromodomain inhibitor. UMB-136 is a promising latency-reversing agent (LRA) for HIV-1 eradication. UMB-136 reactivates HIV-1 in multiple cell models. UMB-136 enhances HIV-1 transcription and increases viral production through the release of P-TEFb[1].

• Target Antigen:

  Epigenetic Reader Domain; HIV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Epigenetics

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/umb-136.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=CC(C2=C(ON=C2C)C)=CC=C1C3=C(N4C(C=NC=C4)=N3)NC5CCCCC5

• Molecular Weight:

  417.50

• References & Citations:

  [1]Huang H, et al. A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. Front Microbiol. 2017 Jun 7;8:1035.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2109805-83-4